136 related articles for article (PubMed ID: 32158439)
41. A katG S315T or an ahpC promoter mutation mediate Mycobacterium tuberculosis resistance to 2-thiophen carboxylic acid hydrazide, an inhibitor resembling the anti-tubercular drugs Isoniazid and Ethionamide.
Franceschelli JJ; Belardinelli JM; Tong P; Loftus B; Recio-Balsells A; Labadié GR; Gordon SV; Morbidoni HR
Tuberculosis (Edinb); 2018 Sep; 112():69-78. PubMed ID: 30205971
[TBL] [Abstract][Full Text] [Related]
42. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
43. A class of hydrazones are active against non-replicating Mycobacterium tuberculosis.
Bonnett SA; Dennison D; Files M; Bajpai A; Parish T
PLoS One; 2018; 13(10):e0198059. PubMed ID: 30332412
[TBL] [Abstract][Full Text] [Related]
44. In vitro anti-tuberculosis activity of azole drugs against Mycobacterium tuberculosis clinical isolates.
Imperiale BR; Cataldi ÁA; Morcillo NS
Rev Argent Microbiol; 2017; 49(4):332-338. PubMed ID: 28919150
[TBL] [Abstract][Full Text] [Related]
45. Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.
Foo CS; Lupien A; Kienle M; Vocat A; Benjak A; Sommer R; Lamprecht DA; Steyn AJC; Pethe K; Piton J; Altmann KH; Cole ST
mBio; 2018 Oct; 9(5):. PubMed ID: 30301850
[TBL] [Abstract][Full Text] [Related]
46. Nitric oxide scavenging and detoxification by the Mycobacterium tuberculosis haemoglobin, HbN in Escherichia coli.
Pathania R; Navani NK; Gardner AM; Gardner PR; Dikshit KL
Mol Microbiol; 2002 Sep; 45(5):1303-14. PubMed ID: 12207698
[TBL] [Abstract][Full Text] [Related]
47. Risk Factors for Multidrug-resistant Tuberculosis.
Rumende CM
Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
[TBL] [Abstract][Full Text] [Related]
48. Purine metabolism in Mycobacterium tuberculosis as a target for drug development.
Parker WB; Long MC
Curr Pharm Des; 2007; 13(6):599-608. PubMed ID: 17346177
[TBL] [Abstract][Full Text] [Related]
49. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system.
Milano A; Pasca MR; Provvedi R; Lucarelli AP; Manina G; Ribeiro AL; Manganelli R; Riccardi G
Tuberculosis (Edinb); 2009 Jan; 89(1):84-90. PubMed ID: 18851927
[TBL] [Abstract][Full Text] [Related]
50. The search for new sterilizing anti-tuberculosis drugs.
Mitchison DA
Front Biosci; 2004 May; 9():1059-72. PubMed ID: 14977529
[TBL] [Abstract][Full Text] [Related]
51. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
52. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.
Pires D; Valente E; Simões MF; Carmo N; Testa B; Constantino L; Anes E
Antimicrob Agents Chemother; 2015 Dec; 59(12):7693-9. PubMed ID: 26438493
[TBL] [Abstract][Full Text] [Related]
53. Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of
de Welzen L; Eldholm V; Maharaj K; Manson AL; Earl AM; Pym AS
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993337
[TBL] [Abstract][Full Text] [Related]
54. Mechanisms of drug resistance in Mycobacterium tuberculosis.
Wade MM; Zhang Y
Front Biosci; 2004 Jan; 9():975-94. PubMed ID: 14766424
[TBL] [Abstract][Full Text] [Related]
55. A Novel Small-Molecule Inhibitor of the
Sukheja P; Kumar P; Mittal N; Li SG; Singleton E; Russo R; Perryman AL; Shrestha R; Awasthi D; Husain S; Soteropoulos P; Brukh R; Connell N; Freundlich JS; Alland D
mBio; 2017 Feb; 8(1):. PubMed ID: 28196957
[TBL] [Abstract][Full Text] [Related]
56. [Population structure analysis of Mycobacterium tuberculosis Beijing family in Japan].
Iwamoto T
Kekkaku; 2009 Dec; 84(12):755-9. PubMed ID: 20077859
[TBL] [Abstract][Full Text] [Related]
57. Development of new anti-tuberculosis drug candidates.
Shi R; Sugawara I
Tohoku J Exp Med; 2010 Jun; 221(2):97-106. PubMed ID: 20467231
[TBL] [Abstract][Full Text] [Related]
58. Detection of a streptomycin-resistant Mycobacterium bovis strain through antitubercular drug susceptibility testing of Tunisian Mycobacterium tuberculosis complex isolates from cattle.
Djemal SE; Camperio C; Armas F; Siala M; Smaoui S; Messadi-Akrout F; Gdoura R; Marianelli C
BMC Vet Res; 2018 Sep; 14(1):296. PubMed ID: 30268120
[TBL] [Abstract][Full Text] [Related]
59. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
60. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
